Ann: Notice of Annual General Meeting/Proxy Form , page-4

re: Ann: Notice of Annual General Meeting/Pro... Hi kippax,

I reckon that the trade sale option is still very much on the EMS agenda because in their ann. report they said

"During the year Eastland registered a new subsidiary, Malaria Research Company Pty Ltd. The purpose of this company is to become the holding company for the Malarial assets. This company will be structured to become the trade sale vehicle for ArTiMist™"

I expect that going fwd they will again use the sub-lingual delivery system (Patented to PP) for another active ingredient. My interest will be in the structure of that deal, manufacturing and distribution rights which can again be sold or whether they decide to do the manufacturing and distribution of the product themselves.

I would hope that doing the Ph 2 and 3 trials for the next product may be easier (or not required) given recent success (hopefully) of the delivery system.

Am still hoping for a release of Ph 3 (prelim) data at the malaria conference this week to get oppies in the money

bluebush